NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

The key rule is that the change cannot be based on information from the trial.

wrong. The key rule is that the amendment of endpoints, should not be made by someone with trial bias such as Dr Bosch or Dr Liau. Therefore Duffy was brought in without previous SAP/SPA/IA knowledge to lead the endpoint amendments.

But then again your knowledge of FDA regulations has always been iffy